Developing, optimizing, and translating next-generation CAR-T cell therapies to treat cancers — with reduced side effects, improved durability, and expanded access including on-site manufacturing.
From bench to bedside — engineering T cells to defeat cancer with greater precision, durability, and reach.
Advancing chimeric antigen receptor T cell therapy for B cell malignancies, CLL, lymphoma, and multiple myeloma. Includes clinical translation, real-world outcomes, and next-generation CAR designs with improved safety profiles.
Expanding CAR-T beyond blood cancers into solid tumors. Lead programs include TSHR-targeted CAR-T for metastatic thyroid cancer (approaching first-in-human trials) and targeting cancer-associated fibroblasts in multiple myeloma.
Investigating how CAR-T cell "aging" and exhaustion drive cancer relapse. Identifying molecular targets to engineer more durable, less exhausted T cells — directly applicable to both blood cancers and solid tumors.
Developing on-site CAR-T biomanufacturing infrastructure at Mayo Clinic to dramatically reduce cost, turnaround time, and access barriers. Studying outpatient CAR-T delivery and remote monitoring to bring therapy to more patients.
Peer-reviewed research, reviews, and preprints from the T Cell Engineering Lab.
Recognizing contributions to cancer research, innovation, and translational medicine.
The T Cell Engineering Lab welcomes applications from postdoctoral fellows, clinical research fellows, and graduate students with a passion for cancer immunotherapy and T cell biology.
We are a collaborative, multidisciplinary team operating at the intersection of fundamental T cell science, translational oncology, and clinical medicine within one of the world's leading academic medical centers.